Qiang Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Qiang Luo has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Bin Liu
Department of Cardiology, The Second Hospital of Jilin University
1 shared publication - Cailing Li
Foshan Meteorological Service, Foshan, China
1 shared publication - Chunsheng Xiao
State Key Laboratory of Polymer Science and Technology Key Laboratory of Polymer Ecomaterials Changchun Institute of Applied Chemistry Chinese Academy of Sciences Changchun P. R. China
1 shared publication - Eui Jung Kim
Department of Chemical Engineering, University of Ulsan, Ulsan 680-749, South Korea
1 shared publication - Guoliang Wang
Key Laboratory of Polymer Ecomaterials Changchun Institute of Applied Chemistry Chinese Academy of Sciences 5625 Renmin Street Changchun 130022 P. R. China
1 shared publication - Guoqing Wang
Jilin University
1 shared publication
Latest Publications
- 2 June 2025
- Published by Elsevier in Biomaterials
- Vol. 324, 123462
Biomaterial-based therapeutic strategies for inflammatory bowel disease
- 2 June 2025
- Published by Elsevier in Biomaterials
- Vol. 324, 123462
Biomaterial-based therapeutic strategies for inflammatory bowel disease
- 5 February 2025
- Published by Wiley in Advanced Materials
- Vol. 37 (11) , e2420171
Myocardia‐Injected Synergistically Anti‐Apoptotic and Anti‐Inflammatory Poly(amino acid) Hydrogel Relieves Ischemia‐Reperfusion Injury
Reperfusion therapy is the most effective treatment for acute myocardial infarction, but its efficacy is frequently limited by ischemia‐reperfusion injury (IRI). While antioxidant and anti‐inflammatory therapies have shown significant potential in alleviating IRI, these strategies have not yielded satisfactory clinical outcomes. For that, a thermo‐sensitive myocardial‐injectable poly(amino acid) hydrogel of methoxy poly(ethylene glycol)45‐poly(L‐methionine20‐co‐L‐alanine10) (mPEG45‐P(Met20‐co‐Ala10), PMA) loaded with FTY720 (PMA/FTY720) is developed to address IRI through synergistic anti‐apoptotic and anti‐inflammatory effects. Upon injection into the ischemic myocardium, the PMA aqueous solution undergoes a sol‐to‐gel phase transition and gradually degrades in response to reactive oxygen species (ROS), releasing FTY720 on demand. PMA acts synergistically with FTY720 to inhibit cardiomyocyte apoptosis and modulate pro‐inflammatory M1 macrophage polarization toward anti‐inflammatory M2 macrophages by clearing ROS, thereby mitigating the inflammatory response and promoting vascular regeneration. In a rat IRI model, PMA/FTY720 reduces the apoptotic cell ratio by 81.8%, increases vascular density by 34.0%, and enhances left ventricular ejection fraction (LVEF) by 12.8%. In a rabbit IRI model, the gel‐based sustained release of FTY720 enhanced LVEF by an additional 7.2% compared to individual treatment. In summary, the engineered PMA hydrogel effectively alleviates IRI through synergistic anti‐apoptosis and anti‐inflammation actions, offering valuable clinical potential for treating myocardial IRI.
- 5 February 2025
- Published by Wiley in Advanced Materials
- Vol. 37 (11) , e2420171
Myocardia‐Injected Synergistically Anti‐Apoptotic and Anti‐Inflammatory Poly(amino acid) Hydrogel Relieves Ischemia‐Reperfusion Injury
Reperfusion therapy is the most effective treatment for acute myocardial infarction, but its efficacy is frequently limited by ischemia‐reperfusion injury (IRI). While antioxidant and anti‐inflammatory therapies have shown significant potential in alleviating IRI, these strategies have not yielded satisfactory clinical outcomes. For that, a thermo‐sensitive myocardial‐injectable poly(amino acid) hydrogel of methoxy poly(ethylene glycol)45‐poly(L‐methionine20‐co‐L‐alanine10) (mPEG45‐P(Met20‐co‐Ala10), PMA) loaded with FTY720 (PMA/FTY720) is developed to address IRI through synergistic anti‐apoptotic and anti‐inflammatory effects. Upon injection into the ischemic myocardium, the PMA aqueous solution undergoes a sol‐to‐gel phase transition and gradually degrades in response to reactive oxygen species (ROS), releasing FTY720 on demand. PMA acts synergistically with FTY720 to inhibit cardiomyocyte apoptosis and modulate pro‐inflammatory M1 macrophage polarization toward anti‐inflammatory M2 macrophages by clearing ROS, thereby mitigating the inflammatory response and promoting vascular regeneration. In a rat IRI model, PMA/FTY720 reduces the apoptotic cell ratio by 81.8%, increases vascular density by 34.0%, and enhances left ventricular ejection fraction (LVEF) by 12.8%. In a rabbit IRI model, the gel‐based sustained release of FTY720 enhanced LVEF by an additional 7.2% compared to individual treatment. In summary, the engineered PMA hydrogel effectively alleviates IRI through synergistic anti‐apoptosis and anti‐inflammation actions, offering valuable clinical potential for treating myocardial IRI.
- 21 November 2020
- Published by Wiley in Chinese Journal of Chemistry
- Vol. 39 (4) , 1009-1021
Surface Modified Persistent Luminescence Probes for Biosensing and Bioimaging: A Review
Persistent luminescence materials (PLMs) are a class of unique luminescent materials that can remain luminescent for a few milliseconds to days without constant excitation. By virtue of the super long decay time, PLMs have been extensively explored in biosensing and bioimaging applications to elimin ate autofluorescence interference and improve signal‐to‐noise ratio in complex samples and tissues. However, nude PLMs often suffer from the poor stability, selectivity, and biocompatibility in biological system and in vivo, which greatly impedes their applications in biomedicine and bioanalysis. Remarkably, surface modification is a viable solution that endows PLMs with span‐new features and can make PLMs suitable for organisms by altering PLMs’ interaction with biological system. In this review, commonly used strategies for surface modification of PLMs are briefly introduced, and the applications of surface modified PLMs in biosensing and bioimaging as well as their challenges are summarized. image
- 21 November 2020
- Published by Wiley in Chinese Journal of Chemistry
- Vol. 39 (4) , 1009-1021
Surface Modified Persistent Luminescence Probes for Biosensing and Bioimaging: A Review
Persistent luminescence materials (PLMs) are a class of unique luminescent materials that can remain luminescent for a few milliseconds to days without constant excitation. By virtue of the super long decay time, PLMs have been extensively explored in biosensing and bioimaging applications to elimin ate autofluorescence interference and improve signal‐to‐noise ratio in complex samples and tissues. However, nude PLMs often suffer from the poor stability, selectivity, and biocompatibility in biological system and in vivo, which greatly impedes their applications in biomedicine and bioanalysis. Remarkably, surface modification is a viable solution that endows PLMs with span‐new features and can make PLMs suitable for organisms by altering PLMs’ interaction with biological system. In this review, commonly used strategies for surface modification of PLMs are briefly introduced, and the applications of surface modified PLMs in biosensing and bioimaging as well as their challenges are summarized. image
- 1 July 2018
- Published by IOP Publishing in Materials Research Express
- Vol. 5 (7) , 075011
Nanoporous nickel films on glass substrate by sol–gel technique
- 1 July 2018
- Published by IOP Publishing in Materials Research Express
- Vol. 5 (7) , 075011
Nanoporous nickel films on glass substrate by sol–gel technique